The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma
- Conditions
- Acute Myeloid Leukemia (AML)Ewing Sarcoma
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- asmaa salama ibrahim
- Target Recruit Count
- 2631
- Registration Number
- NCT06659224
- Locations
- 🇪🇬
Suez Canal University, Ismailia, Egypt
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: D5-PBCR(-) IA armDrug: D5-PBCR(+) IA+Venetoclax arm
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 218
- Registration Number
- NCT06652685
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) Relapse
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 91
- Registration Number
- NCT06648512
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇫🇮FHRB (Finnish Hematology Registry and Clinical Biobank), Vantaa, Finland
🇩🇪Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie und Onkologie, Berlin, Germany
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) RelapseNK Cell
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Not specified
- Target Recruit Count
- 12
- Registration Number
- NCT06641648
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)CAR-T
- Interventions
- Biological: CAR-T Cell Injection
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Zhimin Zhai
- Target Recruit Count
- 9
- Registration Number
- NCT06642025
- Locations
- 🇨🇳
The Second Affliated Hospital of Anhui Medical University, Hefei, Anhui, China
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT06634394
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Kansas, Fairway, Kansas, United States
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 112
- Registration Number
- NCT06565975
- Locations
- 🇫🇷
Kappa Sante, Paris, France
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)/AMLChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 132
- Registration Number
- NCT06563804
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Kansas, Fairway, Kansas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- Drug: TQB3455 tablet+Azacitidine for Injection
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06550713
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University international Hospital, Beijing, Beijing, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
- Interventions
- Drug: QHRD107 capsule，Venclexta and Azacitidine
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT06532058
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
🇨🇳Huai 'an First People's Hospital, Huaian, Jiangsu, China